塞来昔布联合卡培他滨节拍化疗治疗老年患者晚期结肠癌的疗效观察.pdf

• 206 • 现代药物与临床 Drugs Clinic 第 28 卷 第 2 期 2013 年 3 月 塞来昔布联合卡培他滨节拍化疗治疗老年患者晚期结肠癌的疗效观察 李云红 盐城市第二人民医院 肿瘤内科，江苏 盐城 224000 摘 要：目的 探讨塞来昔布联合卡培他滨节拍化疗治疗老年患者晚期结肠癌的临床疗效。方法 回顾性研究 35 例老年晚 期结肠癌病例，所有患者均给予口服卡培他滨 500 mg，2 次/d ，塞来昔布200 mg ，2 次/d ，连续服药直至病情进展，至少2 月后评价疗效以及毒副反应。结果 治疗总有效率为 37.1%，疾病控制率为 77.1%，生活质量总改善率 82.9%，中位疾病进 展时间为 8 个月，中位生存期为 14 个月。所有患者均以Ⅰ、Ⅱ级毒副反应为主，主要为白细胞减少、手足综合征、恶心呕 吐、腹泻、食欲减退等。结论 塞来昔布联合卡培他滨节拍化疗治疗老年晚期结肠癌具有安全、有效、毒副反应小以及患者 依从性好等优点。 关键词：塞来昔布；卡培他滨；节拍化疗；晚期结肠癌 中图分类号：R969.4 文献标志码：A 文章编号：1674 - 5515(2013)02 - 0206 - 04 DOI :10.7501/j.issn.1674-5515.2013.02.027 Clinical observation of metronomic chemotherapy with celecoxib and capecitabine in aged patients with advanced colon cancer LI Yun-hong Department of Oncology, Yancheng Second People’s Hospital, Yancheng 224000, China Abstract: Objective To explore the clinical effect of metronomic chemotherapy with celecoxib and capecitabine in aged patients with advanced colon cancer. Methods The aged patients (35 cases) with advanced colon cancer were studied retrospectively. They were po received capecitabine (500 mg) and celecoxib (200 mg) twice daily until the disease appeared progressive. The efficacy and toxicity were evaluated at least two months after therapy. Results The total effective rate was 37.1%, the disease control rate was 77.1%, the life quality improvement rate was 82.9%, the median time to progression was 8 months, and the median period to survival was 14 months. The patients mainly had I and II side effects, such as leucopenia, hand-food syndrome, nausea, vomiting, diarrhea, and loss of appetite. Conclusion Metronomic chemotherapy with celecoxib and capecitabine in aged patients with advanced colon cancer is effective and safe, at the same time the patients could tolerate metronomic chemotherapy well with little side effect. Key words: celecoxib; capecitabine; metronomic chemo